For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | - | 2,733 | 57 | 55* |
| Research and development | 2,311 | 2,291 | 2,506 | -768* |
| Acquired in-process research and development | - | - | - | -124,291* |
| General and administrative | 1,744 | 1,691 | 2,754 | 4,104* |
| Total operating expenses | 4,055 | 3,982 | 5,260 | -120,956* |
| Gain from operations | -4,055 | -1,249 | -5,203 | 121,011* |
| Change in fair value of warrant liability | 3 | -146 | -26,513 | 6,110* |
| Other income, net | 96 | 188 | 180 | -110* |
| Net (gain) income | -3,962 | -915 | 21,490 | 114,791* |
| Net (loss) income attributable to series c preferred stockholders, basic | - | -290 | 6,407 | -27,962* |
| Net (loss) income attributable to common stockholders, basic | -3,035 | -625 | 15,083 | 142,753 |
| Basic EPS | -0.34 | -0.11 | 2.17 | 91.939 |
| Diluted EPS | -0.34 | -0.11 | 2.09 | 91.939 |
| Basic Average Shares | 8,818,859 | 5,820,903 | 6,965,927 | 1,552,685* |
| Diluted Average Shares | 8,818,859 | 5,820,903 | 7,215,125 | 1,552,685* |
Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc. (TRAW)